About ACELYRIN
ACELYRIN is a company based in Los Angeles (United States) founded in 2020 by Shao Lee Lin.. ACELYRIN has raised $550 million across 3 funding rounds from investors including Marshall Wace, TD Securities and Citadel. ACELYRIN has completed 1 acquisition, including ValenzaBio. ACELYRIN offers products and services including Izokibep and Lonigutamab. ACELYRIN operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Los Angeles, United States
- Founders Shao Lee Lin
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acelyrin, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$550 M (USD)
in 3 rounds
-
Latest Funding Round
$300 M (USD), Series C
Sep 13, 2022
-
Investors
Marshall Wace
& 13 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ACELYRIN
ACELYRIN offers a comprehensive portfolio of products and services, including Izokibep and Lonigutamab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational drug targeting immunology diseases for patient treatment.
Potential therapy for unmet needs in immunology applications.
Unlock access to complete
Funding Insights of ACELYRIN
ACELYRIN has successfully raised a total of $550M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $300 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $300.0M
- First Round First Round
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Series C - ACELYRIN | Valuation | Access Industries | |
| Nov, 2021 | Amount | Series B - ACELYRIN | Valuation | Westlake Village Biopartners , Citadel | |
| Dec, 2020 | Amount | Series A - ACELYRIN | Valuation | Westlake Village Biopartners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ACELYRIN
ACELYRIN has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, TD Securities and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Westlake BioPartners is engaged in biotech venture capital investment.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science and technology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ACELYRIN
ACELYRIN has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ValenzaBio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Treatments for autoimmune and inflammatory diseases are developed.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ACELYRIN
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acelyrin Comparisons
Competitors of ACELYRIN
ACELYRIN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acelyrin
Frequently Asked Questions about ACELYRIN
When was ACELYRIN founded?
ACELYRIN was founded in 2020.
Where is ACELYRIN located?
ACELYRIN is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Who is the current CEO of ACELYRIN?
Shao Lee Lin is the current CEO of ACELYRIN. They have also founded this company.
Is ACELYRIN a funded company?
ACELYRIN is a funded company, having raised a total of $550M across 3 funding rounds to date.
What does ACELYRIN do?
ACELYRIN was established in 2020 and is headquartered in Los Angeles, United States. Operations focus on the biotechnology sector, where therapeutic candidates are developed and commercialized to address severe immunological conditions. Targeted diseases include uveitis, axial spondyloarthritis, hidradenitis suppurativa, and psoriatic arthritis. The company is led by co-founder and CEO Shao Lee Lin.
Who are the top competitors of ACELYRIN?
ACELYRIN's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does ACELYRIN offer?
ACELYRIN offers Izokibep and Lonigutamab.
How many acquisitions has ACELYRIN made?
ACELYRIN has made 1 acquisition, including ValenzaBio.
Who are ACELYRIN's investors?
ACELYRIN has 14 investors. Key investors include Marshall Wace, TD Securities, Citadel, Orbimed, and RTW Investments.